Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Abu-Raddad, Laith J;
Chemaitelly, Hiam;
Ayoub, Houssein H;
Yassine, Hadi M;
Benslimane, Fatiha M;
Al Khatib, Hebah A;
Tang, Patrick;
Hasan, Mohammad R;
Coyle, Peter;
AlMukdad, Sawsan;
+14 more...Al Kanaani, Zaina;
Al Kuwari, Einas;
Jeremijenko, Andrew;
Kaleeckal, Anvar Hassan;
Latif, Ali Nizar;
Shaik, Riyazuddin Mohammad;
Abdul Rahim, Hanan F;
Nasrallah, Gheyath K;
Al Kuwari, Mohamed Ghaith;
Butt, Adeel A;
Al Romaihi, Hamad Eid;
Al-Thani, Mohamed H;
Al Khal, Abdullatif;
Bertollini, Roberto;
(2021)
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75 (1).
e1188-e1191.
ISSN 1058-4838
DOI: https://doi.org/10.1093/cid/ciab909
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.
